Brosgart Named to Mirum Pharmaceuticals Board of Directors
8 June 2021 - - US-based clinical-stage biopharmaceutical company Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has appointed Carol L. Brosgart, M.D., clinical professor of medicine, biostatistics and epidemiology, University of California, San Francisco, as an independent director to its board of directors, the company said.

Dr. Brosgart currently serves as an industry consultant and scientific advisor, and as an independent director for several public and privately held biotechnology companies.

Dr. Brosgart brings extensive clinical, public policy, advocacy and corporate experience to Mirum having held senior management, board and advisory positions in a number of settings.

In addition to various advisory roles, Dr. Brosgart serves as an independent director on the boards of both public and privately held biotechnology companies (Galmed, Abivax, Enochian, and Intrivo Diagnostics) and previously served on the boards of Tobira and Juvaris, until their acquisitions.

Dr. Brosgart's senior management experience in biotechnology and healthcare included Chief Medical officer roles at Alios BioPharma and UCSF Benioff Children's Hospital and Research Center and vice president, Public Health and Policy at Gilead where she was responsible for the clinical development and approval of two antiviral therapies: Viread for the treatment of HIV, and Hepsera for the treatment of chronic hepatitis B.

Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, clinical care, research, and teaching.

Dr. Brosgart also serves in public policy through advocacy, advisory and board roles for numerous organizations and foundations, including the American Liver Foundation, the Hepatitis B Foundation, the San Francisco AIDS Foundation and Forum for Collaborative Research.

Trained as a pediatrician and in public health and preventive medicine, she was among the first physicians in the United States to recognize and treat patients with HIV/AIDS.

Dr. Brosgart was the founding Medical director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development, and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV/AIDS.

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.

Mirum's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia.

Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS.

The NDA has been accepted for priority review by the FDA with a PDUFA action date of September 29, 2021. Additionally, Mirum's marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.

Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, and primary biliary cholangitis.

To augment its pipeline in cholestatic liver disease, Mirum has acquired the exclusive option to develop and commercialize gene therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2, respectively, from Vivet Therapeutics SAS, following preclinical evaluation and investigational new drug-enabling studies.